New Treatments for Rare Mutations in NSCLC
This activity has been planned for clinical oncologists who are managing patients with NSCLC.
At the conclusion of this online enduring activity, participants will be able to:
- Briefly discuss the importance of multigene panel testing in the treatment and management of NSCLC.
- Outline current data on novel therapies for MET, RET, and HER2 mutations that will expand targeted treatment options in NSCLC.
5 mins – Pre-test and Review of Activity Information
45 mins – Presentation
10 mins – Post-test and Evaluation
Joshua Bauml, MD
Assistant Professor of Medicine
Division of Hematology/Oncology
Perelman School of Medicine at the University of Pennsylvania
Dr. Bauml is an Assistant Professor of Medicine at the Perelman School of Medicine at the University of Pennsylvania in Philadelphia, Pennsylvania. He graduated summa cum laude with highest thesis honors from Tufts University in Boston, Massachusetts, and received his Medical Doctorate Degree from Mount Sinai School of Medicine in New York, New York. After his residency at the Mount Sinai Hospital, he completed a fellowship in Medical Oncology at the Hospital of the University of Pennsylvania. His clinical and research interests surround improving clinical outcomes for patients with lung and head and neck cancers.
Ibiayi Dagogo-Jack, MD
Instructor of Medicine
Massachusetts General Hospital
Harvard Medical School
Dr. Dagogo-Jack received her bachelor’s degree from Vanderbilt University and her medical degree from the University of Chicago Pritzker School of Medicine. She trained in Internal Medicine at Brigham and Women’s Hospital. Following residency, she completed Hematology/Oncology fellowship in the combined Massachusetts General Hospital/Dana Farber Cancer Institute program. She is a Medical Oncologist at Massachusetts General Hospital where she specializes in thoracic cancers and conducts clinical and translational research. Her research focuses on understanding mechanisms underlying response and resistance to novel targeted therapies, investigating the role of non-invasive assays in molecular surveillance and detection of lung cancer, and developing clinical trials that evaluate novel drug combinations in lung cancer and mesothelioma.
Planner and Faculty Disclosures
In accordance with the Food and Drug Administration, the speakers have disclosed that there is the potential for discussions concerning off-label uses of a commercial product/device during this educational activity.
Any person who may contribute to the content of this continuing education activity must disclose relevant relationships (and any known relationships of their spouse/partner) with commercial interests whose products or services are discussed in educational presentations. A commercial interest is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Relevant relationships include receiving from a commercial interest research grants, consultant fees, travel, other benefits, or having a self-managed equity interest in a company.
Disclosure of a relationship is not intended to suggest or condone any bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.
Vanessa Carranza, PharmD—has no relevant financial relationships to disclose in relation to the content of this activity.
Joshua Bauml, MD—has disclosed that he is a consultant for AstraZeneca, Ayala, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Genentech, Guardant Health, Janssen, Merck, Regeneron, and Takeda. He receives grant/research support from Amgen, AstraZeneca, Bayer, Carevive Systems, Incyte, Janssen, Merck, and Novartis.
Ibiayi Dagogo-Jack, MD —has disclosed that she is a consultant for AstraZeneca, Boehringer Ingelheim, and Foundation; received travel fees from Array and Pfizer; and receives research support from Array, Genentech/Roche, and Pfizer.
Joan B. Fowler, PharmD, BCPP—has no relevant financial relationships to disclose in relation to the content of this activity.
In support of improving patient care, Creative Educational Concepts is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
- 1.00 AMA PRA Category 1 Credit™